Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00551070 · OUTCOME

Progression-free Survival

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer · Source last updated 2020-12-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Every other cycle

Analysis population: Eligible and Treated Patients

Groups in this outcome

AZD6244

AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
AZD624452

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD624411.3Not reported6.212.9Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        6.2
        upper Limit
        12.9
        value
        11.3
denoms
  1. counts
    1. group Id
      OG000
      value
      52
    units
    Participants
dispersion Type
95% Confidence Interval
groups
  1. description
    AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)
    id
    OG000
    title
    AZD6244
param Type
MEDIAN
population Description
Eligible and Treated Patients
reporting Status
POSTED
time Frame
Every other cycle
title
Progression-free Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice